title: Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.
abstract: The use of retroviral drugs in the treatment of infection by human immunodeficiency virus (HIV) is associated, especially for first generations, with side effects such as lipodystrophy, fatty liver and insulin resistance, which may trigger secondary diabetes or worsen existing diabetes. The use of Glucagon-Like Peptide-1 in obese patients with type 2 diabetes on HIV retroviral as an alternative to insulin therapy is not documented; we report the case of a 47-year-old treated with exenatide when insulin was discontinued. During the first year of treatment, exenatide, in combination with metformin and repaglinide, led to a weight loss of 14 kg and fat mass and waist circumference were respectively reduced from 31 to 25.5% and from 114 to 103 cm. Homeostatic model assessment (HOMA) was used to calculate β-cell secretion which increased from 50 to 78% and insulin sensitivity which increased from 28 to 51%, reflecting a decrease in HbA(1c) by 1.9%. Exenatide may be a new therapeutic option for HIV-infected type 2 diabetes patients undergoing retroviral therapy.
authors.affiliation: Department of Endocrinology, Mouscron Hospital, Belgium. p.oriot@chmouscron.be
authors.forename: P
authors.initials: P
authors.lastname: Oriot
authors.forename: M P
authors.initials: MP
authors.lastname: Hermans
authors.forename: P
authors.initials: P
authors.lastname: Selvais
authors.forename: M
authors.initials: M
authors.lastname: Buysschaert
authors.forename: X
authors.initials: X
authors.lastname: de la Tribonnière
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects; D023241:Antiretroviral Therapy, Highly Active; D002219:Carbamates / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D000077270:Exenatide; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use*; D055105:Waist Circumference / Q000187:drug effects; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D002219:Carbamates; D007004:Hypoglycemic Agents; D010455:Peptides; D010880:Piperidines; D014688:Venoms; C072379:repaglinide; D008687:Metformin; D000077270:Exenatide